2 weeks Bristol Rockets 11% As Investors Question AbbVie’s $8.7 Billion ‘Mistake’Investor's Business Daily

Bristol Myers Squibb stock rocketed Monday after AbbVie’s experimental schizophrenia treatment failed in a pair of midstage studies.
The post Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' appeared first on Inv…

AbbVie (ABBV) · Bristol

12 hours Are Hedge Funds Betting Big On AbbVie Inc. (ABBV)?Insider Monkey X

1 day AbbVie: Upgrading To ‘Strong Buy’ After PullbackSeeking Alpha X

1 day Trade Tracker: Jim Lebenthal buys more AbbvieYouTube X

1 day AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied SetbackInvestor's Business Daily X

1 day Replimune Stock Rallies on BLA Filing for Melanoma Combo DrugZacks X

1 day AbbVie, Nvidia Lead Friday’s Market Cap Stock MoversInvesting.com X

3 days Is Bristol Myers Squibb Stock a Buy?The Motley Fool X

4 days Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?Zacks X

4 days Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on ItZacks X

4 days Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)Seeking Alpha X

5 days Where Will AbbVie Be in 5 Years?Yahoo Finance X

5 days Where Will AbbVie Be in 5 Years?The Motley Fool X

5 days AbbVie’s Ovarian Cancer Drug Elahere Gets Approval in EuropeZacks X

6 days Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the DipThe Motley Fool X

6 days Bristol-Myers Squibb: Buy This Bargain Before It’s GoneSeeking Alpha X

1 week Dividend King AbbVie Just Paid Investors: Here’s How Much They Got24/7 Wall St. X

1 week Pharma Stock Roundup: AZN, BAYRY’s Earnings, ABBV’s Pipeline SetbackZacks X

1 week AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?Zacks X

1 week Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its StockThe Motley Fool X

1 week Final Trades: Bitcoin, Abbvie and Baker HughesYouTube X

1 week Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s ProspectsSeeking Alpha X

1 week Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?Insider Monkey X

2 weeks AbbVie’s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology PortfolioYahoo Finance X

2 weeks Final Trades: Lyft, Meta, United States Oil Fund & AbbvieYouTube X

2 weeks AbbVie And Pfizer: Q3 Dividend Checkup Post-EarningsSeeking Alpha X

2 weeks Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)Seeking Alpha X

2 weeks Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)Seeking Alpha X

2 weeks AbbVie Stock: Keep Calm And Buy The DipSeeking Alpha X

2 weeks Why AbbVie Stock Was Getting Mashed on MondayThe Motley Fool X

2 weeks Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?Zacks X

2 weeks AbbVie Tumbles After New Schizophrenia Drug Fails Two TrialsYahoo Finance X

2 weeks RHHBY or ABBV: Which Is the Better Value Stock Right Now?Zacks X

3 weeks Analyst Report: AbbVie IncYahoo Finance X

3 weeks Market Digest: THRM, DINO, KLAC, OKE, RJF, SYK, META, ABBV, NCLHYahoo Finance X

3 weeks Bristol Myers Squibb Stock Gets Relative Strength Rating UpgradeInvestor's Business Daily X

3 weeks Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY’s Q3 Earnings in FocusZacks X

3 weeks AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPSMarketBeat X

3 weeks Bristol Myers Squibb (BMY) Q3 2024 Earnings Call TranscriptThe Motley Fool X

3 weeks Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS ViewZacks X

3 weeks Bristol Myers Screams To A Year-High After Walloping Profit ExpectationsInvestor's Business Daily X

3 weeks AbbVie: 3 Positives From The Earnings ReportSeeking Alpha X

3 weeks AbbVie Inc. (NYSE:ABBV) Short Interest Up 8.9% in OctoberMarketBeat X

3 weeks AbbVie (ABBV) Q3 2024 Earnings Call TranscriptThe Motley Fool X

3 weeks AbbVie Trumps Q3 Earnings & Sales Estimates, Raises ’24 EPS ViewZacks X

3 weeks AbbVie (NYSE:ABBV) Stock Price Up 3.2% After Dividend AnnouncementMarketBeat X

4 weeks Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key MetricsZacks X

4 weeks AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, RinvoqInvesting.com X

4 weeks AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter BeatInvestor's Business Daily X

4 weeks Pallas Capital Advisors LLC Purchases 9,537 Shares of Bristol-Myers Squibb (NYSE:BMY)MarketBeat X

4 weeks Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’Insider Monkey X

More news +